Is Blackmores Limited a buy at the current share price?

Blackmores Limited (ASX:BKL) shares have dropped 28% since the start of 2016.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Despite reporting a 160% increase in first half profits last week, shares of Blackmores Limited (ASX: BKL) still ended the week down by nearly 5%. This takes the vitamin company's year-to-date share price decline to nearly 28%.

To put this in perspective however, the shares have still gained around 250% over the past 12 months and more than 390% (excluding dividends) over the past five years – long term shareholders, therefore, won't have too much to complain about!

Blackmores, along with Bellamy's Australia Ltd (ASX: BAL), were possibly the two biggest momentum trades of the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) last year and investors must now wonder if the good times are over or whether this is just a temporary bump in the road.

There are a number of reasons that could explain why Blackmores' share price has fallen from more than $220 per share down to $157 in just a matter of months including:

  • Profit taking – Traders and investors who have ridden the wave up over the last year will have wanted to lock in profits before the company released its earnings just in case their was some unexpected surprise or earnings expectations miss.
  • Speculation of Chinese Government intervention – As reported last week, the Chinese government is proposing laws to tighten restrictions on the importation of products such as baby formula and vitamins being sold to consumers through the so called 'grey market'. Renowned fund manager Geoff Wilson cited this as the reason for his recent sell-down in Blackmores saying the risk of a crackdown was just too big to ignore.
  • Increasing scepticism about the efficacy of its products – Although some of its products have a genuine health benefit to consumers, the majority of its products lack rigorous scientific evidence to support their claims. This may seem insignificant while sales are booming (especially into Asia), but voices about this issue are getting louder and this could be seen as a risk moving forward.
  • Valuation concerns – At $220 a share, Blackmores was trading on a trailing price-to-earnings (P/E) ratio of around 83. While this appeared extremely expensive, its forecast P/E ratio for FY16 before the release of its first half results was closer to 37. Although the forecast multiple is not outrageous, with the broader market getting heavily sold off at the start of the year, there was always the risk some investors would get nervous and move to limit their exposure to high valuation companies.
  • Increased threat of competition – The level of growth Blackmores has achieved will naturally bring new competitors into the market looking to get a piece of the action. Although Blackmores has a brand that consumers trust, there is always the risk of new competitors entering the scene with aggressive marketing campaigns that have the potential to impact sales.

What now?

The earnings report released by Blackmores last week confirmed it remains on track to deliver huge earnings growth for the remainder of FY16. Furthermore, according to Commsec, analysts are projecting FY17 earnings per share of $7.18 – more than two-and-a-half times what it earned in FY15.

While this seems extraordinary, there is a good chance that Blackmores could generate profits higher than this especially if its new baby formula venture is successful.

Buy or avoid?

The decision to buy or avoid comes down to whether you believe Blackmores will be able to continue on its current growth trajectory or whether issues like government restrictions will impact the company's sales to foreign markets.

It could be argued that the recent share price decline has already factored in most of these risks, but I feel there could be further uncertainty in the short term and investors should remain watchful for new developments or further falls in the share price before allocating a large portion of their portfolio to Blackmores.

Motley Fool contributor Christopher Georges has no position in any stocks mentioned. Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »